Unknown

Dataset Information

0

Preventive Effects of Dental Pulp Stem Cell-conditioned Media on Anti-RANKL Antibody-Related Osteonecrosis of the Jaw.


ABSTRACT: Medication-related osteonecrosis of the jaw is a serious disease occurring in patients with cancer and osteoporosis, who are undergoing treatment with antiresorptive agents (ARAs) such as bisphosphonate (BP) or denosumab, an antibody targeting receptor activator of NF-κB ligand. Recently, stem cell-based therapy has been shown to be effective in preventing the development of bisphosphonate-related osteonecrosis of the jaw. However, studies on denosumab-related osteonecrosis of the jaw (DRONJ) remain limited. Here, the efficacy of treatment with dental pulp stem cell conditioned media (DPSC-CM) in preventing DRONJ in a murine model was evaluated. Local administration of DPSC-CM into the extraction socket of a mouse with DRONJ decreased the number of empty osteocyte lacunae and the prevalence of ONJ. In tissues surrounding the extraction sockets in the DPSC-CM-treated group, the expression of inflammatory cytokines was attenuated and that of osteogenesis-related molecules was enhanced compared to that in the control group. Further, the expression of Wnt signaling molecules, which had been suppressed, was improved. These findings collectively suggest that DPSC-CM prevents ONJ development in a murine DRONJ model.

SUBMITTER: Kaminogo K 

PROVIDER: S-EPMC11246278 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Preventive Effects of Dental Pulp Stem Cell-conditioned Media on Anti-RANKL Antibody-Related Osteonecrosis of the Jaw.

Kaminogo Kento K   Yamaguchi Satoshi S   Chen Hui H   Yagita Hideo H   Toyama Naoto N   Urata Yusuke Y   Hibi Hideharu H  

Calcified tissue international 20240529 2


Medication-related osteonecrosis of the jaw is a serious disease occurring in patients with cancer and osteoporosis, who are undergoing treatment with antiresorptive agents (ARAs) such as bisphosphonate (BP) or denosumab, an antibody targeting receptor activator of NF-κB ligand. Recently, stem cell-based therapy has been shown to be effective in preventing the development of bisphosphonate-related osteonecrosis of the jaw. However, studies on denosumab-related osteonecrosis of the jaw (DRONJ) re  ...[more]

Similar Datasets

| S-EPMC7064532 | biostudies-literature
| S-EPMC5516172 | biostudies-literature
| S-EPMC9213300 | biostudies-literature
| S-EPMC7907144 | biostudies-literature
| S-EPMC6717901 | biostudies-literature
| S-EPMC9027398 | biostudies-literature
| S-EPMC10509150 | biostudies-literature
| S-EPMC7878993 | biostudies-literature
2021-09-10 | PXD024585 | Pride
| S-EPMC6493760 | biostudies-literature